AllSci News
Brukinsa becomes first BTK inhibitor to beat chemo in frontline MCL
BeOne Medicines (Nasdaq: ONC) reported positive topline results from the Phase III MANGROVE trial showing that zanubrutinib (Brukinsa) plus rituximab...
Moffitt wins USD 1.66 million NCI grant to target MYC-driven inflammation in myelofibrosis
Moffitt Cancer Center has received a USD 1.66 million National Cancer Institute R01 renewal to investigate a MYC-driven inflammatory pathway as a potential...
New York Genome Center aims to lower barriers to spatial multi-omics with NIH funding
New York Genome Center (NYGC) has received a USD 2.68 million NIH R01 grant from the National Human Genome Research Institute to develop a cost-accessible...
Washington Uni explores whether sleep aid suvorexant can slow Alzheimer's pathology
Washington University in St. Louis has received a USD 1.47 million National Institute on Aging R01 renewal to evaluate whether chronic treatment with the...
MSK backed by NCI to explore lethal hyperactivation of WNT, MAPK, and PI3K in colorectal cancer
Memorial Sloan-Kettering Cancer Center has received a USD 1.71 million NCI OT2 award to pursue a counterintuitive approach to colorectal cancer treatment:...
Lilly outsources Verzenios commercialization in China to Innovent, deepening eight-deal partnership
Eli Lilly hands Innovent sole commercialization rights to abemaciclib in mainland China, deepening an eight-deal partnership as Lilly systematically...
Sanofi's Nexviazyme clears path to replace Myozyme in infantile-onset Pompe disease
Sanofi (Nasdaq: SNY) reported that avalglucosidase alfa (Nexviazyme) met all primary and secondary endpoints in the Baby-COMET Phase III study in...
Genentech’s Enspryng advances toward first at-home subcutaneous TED standard of care
Genentech announced that the US FDA has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab)…
Grünenthal advances NOP agonist into efficacy testing after clear Phase I
Germany-based Grünenthal Group has reported the successful completion of a Phase I trial for its proprietary nociceptin receptor (NOP) agonist, an...
Genmab's epcoritamab beats chemotherapy in earlier relapsed DLBCL, opening chemo-free path
Denmark-based Genmab A/S (Nasdaq: GMAB) reported that the Phase III EPCORE DLBCL-4 trial met its primary endpoint, with epcoritamab (Epkinly) plus...
EU approves Enhertu as first tumor-agnostic HER2 therapy
The European Commission has approved Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy and antibody drug conjugate in the EU, extending…
FDA Fast Track clears path for Satellos’ mutation-agnostic DMD therapy ahead of Phase II readouts
Toronto-based Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) announced receipt of US FDA Fast Track Designation for SAT-3247, an oral small molecule…
Neurogene's gene therapy shows sustained milestone gains in Rett syndrome through 30 months
New York-based Neurogene (Nasdaq: NGNE) reported updated Phase I/II data for NGN-401, an AAV9 gene therapy delivering a full-length human MECP2 transgene,...
Viatris ready to seek Japan approval for Tarpeyo in IgAN after positive readout
Viatris Inc. (Nasdaq: VTRS) is targeting submission of a New Drug Application to Japan's Ministry of Health, Labour and Welfare (MHLW) for Tarpeyo/Kinpeygo...
CraniUS wins NIH support to advance NeuroPASS brain drug delivery platform toward glioblastoma trial
Baltimore-based CraniUS Therapeutics has received an initial USD 1.1 million award through the NIH Blueprint MedTech Optimizer Program, with the potential...
The AllSci Brief
Systematic R&D and deal news. Daily.